Skill Guide

Clinical trial lifecycle knowledge (Phase I-IV, ICH-GCP, CDISC CDASH/SDTM/ADaM standards)

The integrated understanding of the end-to-end process for developing and monitoring a pharmaceutical product from first-in-human studies (Phase I) through post-marketing surveillance (Phase IV), governed by ethical and quality standards (ICH-GCP) and enabled by standardized data collection, tabulation, and analysis models (CDISC CDASH, SDTM, ADaM).

This skill ensures regulatory submission success and data integrity, directly impacting a drug's time-to-market and commercial viability. It mitigates catastrophic compliance and data quality risks that can lead to regulatory rejection, trial delays, and significant financial loss.

1 Careers

1 Categories

9.1 Avg Demand

15% Avg AI Risk

How to Learn Clinical trial lifecycle knowledge (Phase I-IV, ICH-GCP, CDISC CDASH/SDTM/ADaM standards)

Focus on foundational terminology (e.g., IND, CSR, CRF, IRB), the core objectives and risk profile of each clinical trial phase (I-IV), and the high-level principles of ICH-GCP (investigator responsibilities, informed consent, data integrity).

Move to applied knowledge: understand the critical links between an SAP (Statistical Analysis Plan) and ADaM datasets, design a mock Case Report Form (CRF) aligned with CDASH, and conduct a mock audit identifying common GCP non-compliance findings (e.g., protocol deviations, documentation gaps).

Master the strategic integration: lead a cross-functional team to align a trial protocol's data collection strategy with both regulatory requirements (ICH E6(R3)) and CDISC standards to streamline database lock and submission. Mentor on the lifecycle impact of early data architecture decisions.

Practice Projects

Beginner

Case Study/Exercise

CRF Design & Protocol Mapping

Scenario

You are given a simplified Phase II protocol for a new hypertension drug. Your task is to translate a single study endpoint (e.g., change in systolic blood pressure at Week 12) into the data collection elements required on a CRF.

How to Execute

1. Identify all required data points (subject ID, visit dates, baseline BP, Week 12 BP, concomitant meds). 2. Map each to a CDASH domain (e.g., VS for vital signs, CM for concomitant meds). 3. Draft the CRF pages, specifying field names, units, and edit checks (e.g., BP must be numeric). 4. Review against ICH-GCP principles for clarity and subject privacy.

Intermediate

Case Study/Exercise

SDTM Mapping & Compliance Gap Analysis

Scenario

You are handed a raw dataset from a completed Phase III trial. The dataset has column names like 'VSDAT', 'BP_SYS', 'VISIT'. You must map it to the SDTM 'VS' (Vital Signs) domain and identify any compliance or structural issues.

How to Execute

1. Use the SDTM Implementation Guide (IG) to define the required 'VS' domain variables (e.g., USUBJID, VSTESTCD, VSORRES, VISITNUM). 2. Create a mapping specification from the source to target variables. 3. Flag issues: Is VISITNUM derivable? Are there missing mandatory 'SUPPQUAL' qualifiers? Does the data meet CDISC controlled terminology? 4. Document findings and propose remediation steps.

Advanced

Case Study/Exercise

End-to-End Submission Package Simulation

Scenario

You are the data lead for a New Drug Application (NDA) submission. The FDA reviewer has issued a question about the primary efficacy analysis. You must trace the data from the CRF through to the final ADaM dataset and Analysis Results Metadata (ARM).

How to Execute

1. Demonstrate the traceability: CRF -> SDTM (AE, DM, QS) -> ADaM (ADSL, ADEFF). 2. Show how the SAP defines the analysis population and endpoint calculation. 3. Present the ADaM dataset and ARM, highlighting how the analysis results (e.g., LS Means) are derived. 4. Prepare a response explaining any protocol deviations impacting this data and how they were handled per GCP and SAP.

Tools & Frameworks

Standards & Guidelines

ICH E6(R2) GCPICH E8(R1) General Considerations for Clinical StudiesCDISC CDASH v2.1CDISC SDTM v3.4 / SDTMIG v3.4CDISC ADaM v2.1 / ADaMIG v1.3

The non-negotiable rulebook. ICH-GCP governs ethical conduct and data quality. CDISC standards are the language for regulatory submission; mastery is required for any data-related role in pharma.

Software & Platforms

SAS (Base, STAT, Macro)R (for analysis, CDISC package use)Medidata Rave / Oracle ClinicalPinnacle 21 (OpenCDISC)Visual Review Tools (JMP, Tableau for data cleaning)

SAS remains the industry standard for SDTM/ADaM creation and validation. EDC systems (Rave, OC) are the data source. Pinnacle 21 is the validation tool; understanding its 'Rule Sets' is critical for submission readiness.

Interview Questions

Answer Strategy

Structure the answer chronologically: 1) Protocol & CRF Design (reference GCP 6.1 & CDASH), 2) Data Entry & Cleaning (EDC, edit checks), 3) Medical Coding (MedDRA), 4) Data Transfer & Mapping to SDTM, 5) Validation with Pinnacle 21, 6) Database Lock procedures. Emphasize the 'by design' approach (e.g., CRF annotating for SDTM).

Answer Strategy

Test problem-solving, cross-functional communication, and knowledge of ADaM traceability. The answer should show a systematic, documented approach that prioritizes data integrity and regulatory guidance.